ASKA Pharmaceutical Co., Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Tokyo Japan (1929)

Organization Overview

First Clinical Trial
2019
NCT03931915
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

ASKA Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

leuprolide (lupron) (1 trial)

relugolix (ORGOVYX) (1 trial)

Drugs in Phase 2 Trials (1)

rifaximin (xifaxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Endometriosis (Phase 3)

Intestinal Pseudo-Obstruction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3